Pedskin Research dermatology innovations

Does your child have uncontrolled psoriasis?

Does your child have uncontrolled psoriasis?

Is your child experiencing problems with their skin becoming scaly and inflamed, most often on the scalp, elbows, or knees?

There is a new clinical trial for young patients aged 6 to 17 who have moderate to severe psoriasis.

Pedskin Research clinical trials for children

Is your child experiencing problems with their skin becoming scaly and inflamed, most often on the scalp, elbows, or knees?

There is a new clinical trial for young patients aged 6 to 17 who have moderate to severe psoriasis.

Learn More

About the Trial

Our current clinical trial focuses on pediatric patients aged 6 to 17 years with moderate to severe psoriasis.

Importantly, participants are only required to have psoriasis affecting approximately 5% of their body surface area, making it accessible to a broader range of patients.

The trial focuses on evaluating the effectiveness and safety of the medication OTEZLA in younger age groups.

OTEZLA, produced by Amgen, has been successfully used in adults (18 years and older) with moderate to severe chronic plaque psoriasis for several years.

This is an open-label trial, meaning all enrolled subjects will receive the medication.

The primary objective is to assess how OTEZLA performs in patients aged 6 to 17, ensuring efficacy comparable to its adult use. Additionally, we will closely monitor for any new safety concerns, a standard practice when extending a medication’s indication to a lower age group.

Meet Our Medical Director

Mercedes E. Gonzalez M.D.
Mercedes E. Gonzalez M.D.

Dr. Mercedes E. Gonzalez is a board-certified pediatric dermatologist. After graduating from Emory University, she earned her degree at Rutgers–New Jersey Medical School in 2004. Always drawn to working with children, she accepted the prestigious pediatrics program at the Morgan Stanley Children’s Hospital of New York–Columbia University where she solidified her interest in treating skin disorders. She then completed a dermatology residency followed by a clinical fellowship in pediatric dermatology at the top-ranked New York University (NYU) Department of Dermatology.

Her gentle, child-friendly bedside manner, combined with her broad knowledge of childhood skin diseases and their treatments, make her the preferred pediatric dermatologist in Miami. In addition to practicing medicine, Dr. Gonzalez currently serves as a clinical assistant professor at The FIU Herbert Wertheim School of Medicine and The Phillip Frost Department of Dermatology at Miller School of Medicine.

Dr. Gonzalez serves as the principal investigator on numerous clinical trials and has a special interest in severe skin diseases in children. She lectures regularly at dermatology conferences and to medical students and residents and is the co-editor of 3 dermatology textbooks, including the recently published 2nd edition of Goodheart’s Same Site Differential Diagnosis, and has published over 50 journal articles.

  • Board-certified pediatric dermatologist.

  • Graduated from Emory University.

  • Earned her degree at rutgers–New Jersey Medical School in 2004.

  • Dr. Gonzalez accepted the prestigious pediatrics program at the Morgan Stanley Children’s Hospital of New York–Columbia University where she solidified her interest in treating skin disorders.

  • She then completed a dermatology residency at the top-ranked New York School of Medicine, followed by a clinical fellowship in pediatric dermatology.

Pedskin Research treatment for skin conditions

Join Our Free Webinar
New Treatments for
Psoriasis in Young Patients

📅Date to Be Determined

ABOUT THIS WEBINAR

During the webinar, we will unravel the factors contributing to pediatric psoriasis. Understanding the root causes is crucial for effective management and tailored treatment strategies.

We will discuss various medications used in treating pediatric psoriasis, shed light on their efficacy and safety profiles. The goal is to provide insights into the existing options available for young patients.

Our webinar will feature a segment on new medications currently being investigated in clinical trials. We will explore how medicines with a proven track record in treating adult psoriasis are now being considered for pediatric patients, presenting promising alternatives for the younger demographic.

Learn more about this trial and see if your child is a candidate.

Pedskin Research pediatric dermatology

FILL OUT THE FORM BELOW
AND JOIN OUR PSORIASIS WEBINAR

Psoriasis Webinar
Opt-In

Psoriasis Solutions: A Pioneering Clinical Trial for Young Patients.

“Our wounds are often the openings into the best and most beautiful part of us.”

Psoriasis Solutions: A Pioneering Clinical Trial for Young Patients.

Psoriasis Solutions: A Pioneering Clinical Trial for Young Patients.

Pedskin Research pediatric dermatology

Frequently Asked Questions

The medication is called OTEZLA, and it has been on the market for several years. It is produced by Amgen and has been primarily used to treat moderate to severe chronic plaque psoriasis in adults.

OTEZLA has been on the market for several years, primarily indicated for adults aged 18 and older with moderate to severe chronic plaque psoriasis.

This clinical trial is an open-label trial, meaning all enrolled subjects will receive the medication. Unlike some trials that use a placebo group, this design aims to evaluate how OTEZLA works in pediatric patients aged 6 to 17 years.

The trial aims to expand the indication of OTEZLA to a lower age group. Evaluating its effectiveness and identifying any potential safety concerns in this younger demographic is crucial for obtaining regulatory approval for pediatric use.

To enter the trial, individuals only need to have psoriasis covering about 5% of their body surface area. This inclusivity allows a broader range of patients to participate.

Unlike some other treatments that involve injections, OTEZLA is an oral medication in tablet form. This makes it a more convenient option for pediatric patients, as it is taken once a day.

The trial period is six months. Following this phase, subjects enrolled in the trial have the option to roll over into a longer-term open-label trial, contributing to the understanding of the medication’s sustained impact.

Parents and caregivers interested in the trial can discuss eligibility and participation with their healthcare provider. The trial offers an opportunity to explore OTEZLA as a potential treatment option for pediatric psoriasis, providing valuable insights into its effectiveness and safety in this age group.

How Successful
are the Trials?

About Our
Upcoming Webinar